Reviewed by Michael Gill, B. Sc.
25 Cll Clinical Trials Near Me
Top Hospitals for Cll Clinical Trials
Image of Ohio State University Comprehensive Cancer Center in Ohio.
Ohio State University Comprehensive Cancer Center
8Active Trials
29All Time Trials for Cll
2008First Cll Trial
Top Cities for Cll Clinical Trials
Cll Clinical Trials by Phase of Trial
Phase < 1 Cll Clinical Trials
1Active Cll Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
Cll Clinical Trials by Age Group
18+ Cll Clinical Trials
108Active Cll Clinical Trials
Most Recent Cll Clinical Trials
Top Treatments for Cll Clinical Trials
Treatment Name
Active Cll Clinical Trials
All Time Trials for Cll
First Recorded Cll Trial
Pharmacological Study
Recently Completed Studies with FDA Approved Treatments for Cll
Precision BioSciences, Inc.
CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
Medical College of Wisconsin
M.D. Anderson Cancer Center

What Are CLL Clinical Trials?

Chronic lymphocytic leukemia (CLL) is a kind of cancer that starts in the lymphocytes (white blood cells) in the bone marrow and then goes into the blood. One characteristic of CLL is that cancer cells usually build slowly, and the disease isn’t symptomatic for a few years. That accounts for the “chronic” in “chronic lymphocytic leukemia.” Eventually, the cells spread to the liver, spleen, and lymph nodes.

There is no cure for this cancer, but CLL clinical trials focus on better treatment and management options.

Why Is CLL Being Studied Through Clinical Trials?

According to the American Cancer Society, there have been approximately 60,650 new cases of leukemia and 24,000 deaths from leukemia in 2022. Of these, 20,160 are new cases of CLL. There have also been approximately 4,410 deaths from CLL. CLL clinical trials are necessary since CLL accounts for approximately a quarter of all new cases of leukemia. In fact, for the average person, the lifetime risk of getting CLL is 1 in 175 (0.57%).

What Are the Types of Treatments Available for CLL?

CLL grows slowly, and patients don’t always need to be treated immediately. Healthcare professionals may suggest chemotherapy, targeted therapy drugs, monoclonal antibodies, or stem cell transplants, depending on when treatment is needed. Patients may need to undergo radiation therapy, surgery, or leukapheresis in more severe cases. CLL clinical trials look at promising new procedures and treatments so healthcare professionals can learn how to manage the disease better.

What Are Some Recent Breakthrough Clinical Trials for CLL?

A few recent CCL clinical trials have resulted in breakthrough research on treatment options.

2021: Triplet Therapy – A phase II clinical trial evaluated the experimental triplet therapy consisting of acalabrutinib, venetoclax, and obinutuzumab. 86% of participants showed a significant response over two years, after which no minimal residual disease (MRD) was detected in the patients’ bone marrow.

2022: Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy – In 2010, two patients with end-stage CLL received CAR T-cell therapy and were in remission. Over a decade later, activated CAR T-cells are still active in their blood, keeping the cancer at bay. This is the longest-known CLL remission after this type of therapy.

What Are Some of the Key Opinion Institutions Conducting CLL Clinical Trial Research?

The University of Texas MD Anderson Cancer Center

The MD Anderson Cancer Center is a comprehensive cancer center in Texas. In addition to being one of the original three comprehensive cancer centers in the U.S., it’s also the largest cancer center in the U.S. The center runs various CCL clinical trials to find treatments, focusing on shifting from cytotoxic chemotherapy to well-tolerated oral therapies. The MD Anderson Cancer Center’s current CCL clinical trials include those on the comparison of different dosages of ibrutinib, the efficacy of venetoclax and ibrutinib, and more.

The James – The Ohio State University Comprehensive Cancer Center

The James is a comprehensive cancer center focusing on scientific research and patient-centered care. Because it’s National Cancer Institute (NCI)-designated, it can conduct phase I and II clinical trials on novel anticancer drugs. The James’ CCL clinical trials include those focusing on ARQ 531, venetoclax, ibrutinib, and more.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 13th, 2021

Last Reviewed: October 7th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.